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Abstract 26 
Existing in vitro models of human skeletal muscle cannot recapitulate the organization and 27 
function of native muscle, limiting their use in physiological and pharmacological studies. Here, 28 
we demonstrate engineering of electrically and chemically responsive, contractile human 29 
muscle tissues ("myobundles") using primary myogenic cells. These biomimetic constructs 30 
exhibit aligned architecture, multinucleated and striated myofibers, and a Pax7+ cell pool. They 31 
contract spontaneously and respond to electrical stimuli with twitch and tetanic contractions. 32 
Positive correlation between contractile force and GCaMP6-reported calcium responses 33 
enables non-invasive tracking of myobundle function and drug response. During culture, 34 
myobundles maintain functional acetylcholine receptors and structurally and functionally mature, 35 
evidenced by increased myofiber diameter and improved calcium handling and contractile 36 
strength. In response to diversely acting drugs, myobundles undergo dose-dependent 37 
hypertrophy or toxic myopathy similar to clinical outcomes. Human myobundles provide an 38 
enabling platform for predictive drug and toxicology screening and development of novel 39 
therapeutics for muscle-related disorders. 40 
Impact Statement 41 
A novel bioengineered human skeletal muscle model with accurate physiological and 42 
pharmacological responses may provide a useful tool for preclinical testing. 43 
Introduction 44 
 Development of human in vitro systems for basic biological studies and drug discovery is 45 
motivated by the need to improve outcomes in human patients and alleviate ethical 46 
considerations demanding a reduction in the use of animals(1, 2). While significant progress has 47 
been made towards predictive in vitro models for liver, lung, and cardiac tissues(2), a functional 48 
model of human skeletal muscle has not been described. This is of particular concern as there 49 
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are a wide range of metabolic, neuromuscular, and dystrophic disorders involving skeletal 50 
muscle that are under investigation and still lacking therapies. Skeletal muscle is also central to 51 
diseases with high societal impact and those that do not have adequate animal models, 52 
including diabetes, obesity, and different dystrophies. Furthermore, through secretion of 53 
contraction-dependent myokines, skeletal muscle has been strongly implicated in organ-organ 54 
interactions including processes as diverse as cognition, inflammation, cancer, and aging(3). 55 
The need for an accurate preclinical model of human skeletal muscle was exemplified by the 56 
market withdrawal of cerivastatin that was well tolerated in mice but caused fatal 57 
rhabdomyolysis in humans(4, 5).  58 
 Expansion of primary human myoblasts and formation of myotubes in two-dimensional 59 
(2D) systems is well known, however, these cultures are difficult to maintain over long times, 60 
lack the architecture of native muscle, and require complex media components to initiate 61 
spontaneous contractions(6-8). The contractile force of single, in vitro cultured human myofibers 62 
can be measured(9), though such a system is limited by its inability to investigate biochemical 63 
changes or cell-matrix interactions that can be critical in different pathologies including muscle 64 
dystrophies and wasting disorders(10). While three-dimensional (3D) culture models of rodent 65 
skeletal muscle have measureable contractile force(11-15) and can be applied to drug 66 
testing(15) and disease modeling(16), in vitro 3D systems using primary human myoblasts rely 67 
on measurements of passive force(17-19) which is not specific to functional skeletal muscle.  68 
 Here, we describe a biomimetic human skeletal muscle culture system ("myobundle") 69 
amenable to studies of contractile function and biochemical changes in response to a wide 70 
range of stimuli. Conditions for primary myogenic cell expansion and 3D tissue formation were 71 
optimized to reproducibly obtain contractile myobundles consisting of aligned, cross-striated 72 
myofibers and a pool of cells expressing the satellite cell marker Pax7. In response to electrical 73 
and pharmacological stimuli, myobundles exhibited forceful contractions and calcium transients 74 
which could be non-invasively measured to track physiological responses and functional 75 
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maturation over time. Reproducible functional characteristics were obtained using cells from 76 
nine different donors and one commercial source. Similar to clinical outcomes in humans, when 77 
pharmaceutically challenged, myobundles experienced enhanced contractile performance in 78 
response to a steroid-like substance, underwent autophagic myopathy following administration 79 
of an anti-malarial agent, and exhibited statin-induced weakness and lipid accumulation.  80 
Results 81 
Structure and Composition of Myobundles  82 
Myogenic cells were isolated from human muscle biopsies and expanded for 3-5 83 
passages, when they contained a significant fraction of muscle precursors positive for desmin 84 
and MyoD (Figure 1 – figure supplement 1). Engineered human skeletal muscle   ‘myobundles’  85 
were generated using a hydrogel molding technique (Figure 1A, Figure 1 – figure supplement 2) 86 
we developed for rodent cells(13, 14). Following hydrogel compaction for 3-5 days, low serum 87 
media was applied to induce myofiber formation and differentiation. After an additional 3-5 days, 88 
the myobundles began to spontaneously twitch (Video 1), which was previously reported only in 89 
rodent 3D muscle constructs(11). After two-week culture, the myobundles contained densely 90 
packed and aligned myofibers embedded in a laminin-rich matrix (Figure 1B) and surrounded at 91 
the periphery by vimentin+ fibroblasts (Figure 1 – figure supplement 3A-C). Mature structure of 92 
the myofibers was evident by the expression of myosin heavy chain (MYH), sarcomeric alpha-93 
actinin (SAA) cross-striations, and multiple myogenin+ nuclei (Figures 1C-E and Figure 1- figure 94 
supplement 2B-C). Of functional importance, acetylcholine receptors, which are necessary for 95 
neuromuscular junction formation, were present at the myofiber surface (Figure 1F). While the 96 
majority of expanded myogenic cells fused to form myofibers, a fraction of cells continued to 97 
express the satellite cell marker Pax7 (Figure 1G), suggesting regenerative capacity as 98 
described in a rat culture model(14). With time in culture, structural maturation of myobundles 99 
was evident from the progressive increase in myofiber diameter (13.5 ±1.5 µm and 21.8 ± 2.8 100 
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µm at 1 and 4 weeks of culture, Figure 1H, Figure 1 – figure supplement 3D) and expression of 101 
the muscle-specific proteins (MYH, SAA, and muscle creatine kinase (MCK), Figure 1I), while 102 
myofiber length and myonuclei number (524±70 and 7±3.6, respectively, at 3 weeks of 103 
differentiation) remained relatively steady with time of culture (Figure 1 – figure supplement 4). 104 
Contractile Force Generation of Myobundles 105 
The amplitude of induced contractile force by electrical or chemical stimulation is a key 106 
parameter used to evaluate skeletal muscle function both in vivo and ex vivo on isolated muscle 107 
fibers (20, 21). To optimize contractile force output of myobundles, myogenic cells were 108 
expanded in media containing either bFGF(22) or EGF(23). Despite comparable myoblast purity 109 
and myofiber formation in 2D culture, myobundles made of EGF-expanded cells had superior 110 
contractile function (Figure 2 – figure supplement 1). In addition to spontaneous contractions, 111 
myobundles also contracted in response to electrical stimulation (Video 2) and, similar to native 112 
muscle(24), exhibited stronger contraction with an increase in stimulation frequency and 113 
myobundle length (Figure 2A-B, Figure 2 – figure supplement 2). In concert with observed 114 
structural maturation, amplitudes of twitch and tetanus force in myobundles increased over four 115 
weeks in culture (Figure 2C), while twitch kinetics remained unchanged (Figure 2D).  116 
 To evaluate the robustness of the developed methodology, we expanded and utilized 117 
cells from nine donor muscle samples (obtained by needle biopsy or surgical waste) and one 118 
commercially available myoblast source (Lonza). Expanded cells from all ten sources formed 119 
functional myobundles that contracted in response to electrical stimulation with an average 120 
specific force of 2.1 ± 0.9 mN/mm2 and 7.0 ± 2.2 mN/mm2 for twitch and tetanus, respectively 121 
(Figure 2E). The average tetanus force was similar to values measured in fetal human 122 
muscle(25) and an order of magnitude lower than values reported for adult muscle(25, 26), 123 
while average tetanus-to-twitch ratio (3.5 ± 0.8, Figure 2E) was within the normal adult 124 
range(26). The kinetic parameters of twitch contraction were also evaluated for each donor 125 
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sample (Figure 2F) and were on average two-fold slower than those of adult human muscle(21) 126 
and comparable to those of single in vitro cultured human myotubes(9). 127 
Calcium Handling of Myobundles 128 
To expand the utility of the myobundle platform, we incorporated a capability for non-129 
invasive real-time monitoring of calcium transients in myobundles as calcium handling is critical 130 
to normal muscle function and can be affected by pathological conditions including dystrophic 131 
disorders and malignant hyperthermia(27). Expanded myogenic cells were lentivirally 132 
transduced with a calcium indicator, GCaMP6(28), driven by a muscle-specific promoter, 133 
MHCK7(29), prior to myobundle formation. As a result, robust expression of GCaMP6 in 134 
differentiated myofibers (Figure 3A) allowed detection of both spontaneous and electrically 135 
stimulated calcium transients in myobundles (Figure 3B, Video 3) under a variety of conditions. 136 
In response to 10 Hz (tetanic) vs. single (twitch) stimuli, the amplitude of calcium transients 137 
increased (Figure 3C-D), as measured by normalized change in fluorescence intensity (ΔF/F), 138 
similar to the increase in contractile force with tetanic stimulation. Additionally, with longer time 139 
in culture, calcium transient amplitude increased (Figure 3D) and correlated with the contractile 140 
force amplitude measured in the same bundles (Figure 3 – figure supplement 1). 141 
  We further tested the functionality of calcium-handling machinery in myobundles by 142 
biochemical stimulation with caffeine and acetylcholine (ACh). By opening of ryanodine 143 
receptors, caffeine is known to generate concentration-dependent calcium release and 144 
contraction in skeletal muscle (27, 30), as was observed in myobundles from different donors 145 
(Figure 3 – figure supplement 2, Video 4). ACh is released at the neuromuscular junction to 146 
stimulate muscle contraction via opening of ligand-gated Na/K-permeable channels and voltage-147 
gated Ca channels, while ACh receptors are a target of different muscle relaxants and 148 
toxins(31). The degree of calcium release in response to a bolus of 10 mM ACh (Figure 3E, 149 
Video 5) was comparable to that from electrically stimulated tetanus (Figure 3F) and unchanged 150 
throughout the entire culture period (Figure 3 – figure supplement 3A). Tubocurarine, a muscle 151 
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relaxant, blocked ACh (but not electrically) induced calcium transients (Figure 3F) and 152 
contractions (Figure 3 – figure supplement 3B-C), mimicking the neuromuscular block observed 153 
in vivo(32).  154 
Drug Testing of Myobundles 155 
We evaluated the potential application of myobundles as a preclinical test bed by 156 
studying their responses to three classes of pharmaceutical agents with a broad range of known 157 
effects. Statins are widely prescribed to prevent coronary artery disease, however even at 158 
normal doses some of them can induce significant myopathic weakness and rhabdomyolysis 159 
after as early as two weeks of use(5, 33). We tested the effects of lovastatin and cerivastatin at 160 
their clinically-relevant dose ranges (100-fold higher for lovastatin due its lower bioavailability 161 
and bioactivity(34, 35)) encompassing both maximum therapeutic blood serum concentrations 162 
and higher doses known to accelerate myopathic induction(33). In our studies, 2-week 163 
application of each statin was well tolerated in the myobundles derived from two of three donors 164 
at their respective therapeutic doses, while higher doses induced significant contractile 165 
weakness in the myobundles from all donors (Figure 4A-B). Unlike human myobundles that 166 
replicated clinical response, murine engineered muscle tissues in previous studies exhibited a 167 
sharp decrease in contractile function even at the lowest statin dose tested(15). Human 168 
myobundles also recapitulated the histopathology of statin-associated myopathy characterized 169 
by dose-dependent lipid accumulation(5) (Figure 4C).  170 
We also challenged myobundles with the anti-malarial agent chloroquine for one week to 171 
evaluate its effects on autophagy, a conserved lysosomal pathway in both physiological and 172 
pathological conditions(36). With increasing doses of chloroquine, myobundles from all donors 173 
exhibited a decrease in contractile force generation (Figure 4D), which was associated with the 174 
autophagic buildup marked by conversion of LC3B-I to LC3B-II and a decrease in the 175 
expression of the contractile protein SAA (Figure 4E-F). These outcomes were consistent with 176 
autophagic-related myopathy seen in humans treated with chloroquine(36, 37). Similar 177 
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biochemical responses to chloroquine including accumulation of LC3B-II and reduction of 178 
contractile proteins was also observed in 2D cultures (Figure 4 – figure supplement 1). 179 
Clenbuterol is a β2-adrenergic agonist with both short and long-term concentration-180 
dependent effects on muscle, improving contractile force and hypertrophy at low concentrations, 181 
while inducing apoptosis and necrosis at high concentrations(38).   Clenbuterol   and   other   β-182 
agonists are under investigation for prevention of muscle wasting(39), however, species-183 
dependent differences in their anabolic effects limit the usefulness of preclinical animal 184 
studies(40). In our studies, both acute and chronic application of clenbuterol induced an in vivo-185 
like biphasic dose-dependent effect on contractile force generation of myobundles (Figure 4G-186 
H) with the typical anabolic response and stronger contractions at 0.1 µM and diminished 187 
contractile response above 1 μM. The observed positive inotropic effect of 0.1 µM clenbuterol 188 
was partially attributed to myofiber hypertrophy (Figure 4I) and was confirmed in myobundles 189 
from multiple donors, resulting in an average force increase of 43.2 ±10.8% (Figure 4 – figure 190 
supplement 2). Collectively, these results confirm the functional similarity of myobundles to 191 
human muscle tissue and validate their potential use in the future predictive studies of muscle 192 
physiology. 193 
DISCUSSION 194 
 We described the development and validation of the ‘myobundle‘, a biomimetic human 195 
skeletal muscle culture platform for clinically relevant in vitro studies of muscle physiology and 196 
drug development. Myobundles recapitulate key functional aspects of human skeletal muscle 197 
including a functioning contractile apparatus, responsive acetylcholine and   β2-adrenergic 198 
receptors, and physiological calcium handling, all of which are involved in pharmacological side 199 
effects in humans(41). Long-term electrical and chemical responsiveness of myobundles allow 200 
for both acute and chronic physiological and pharmacological tests. Reproducibility and 201 
robustness of the system were demonstrated using biopsies from multiple donors and a 202 
commercial cell source. Correlated force generation and calcium transient responses recorded 203 
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via the use of genetically encoded calcium indicators(28) enabled continuous optical monitoring 204 
of the relationship between stimuli and functional effects, thus bridging a significant gap in 205 
current testing methods(1).  206 
 Existing methods to measure contractile function of human muscle in vitro rely on acute, 207 
single-time use of intact muscle fibers isolated from patient biopsies(20). While 2D and 3D 208 
cultures can be used to form de novo muscle fibers from human myogenic cells, existing 209 
methods fail to reproduce a comprehensive range of myofiber physiological responses, such as 210 
twitch, tetanus, and chemically induced contractions. Compared to previous 3D culture 211 
studies(18, 19), a relatively high cell density, specific hydrogel and media compositions, and 212 
dynamic culture conditions(42) used in our system may have all contributed to the robust 213 
formation of functional human engineered muscle. Under these conditions, the ability to 214 
generate large numbers (>1000) of contractile myobundles from a single donor biopsy allowed 215 
us to perform traditional physiological and biochemical measurements in both acute and chronic 216 
settings and for multiple testing compounds and conditions. Electrically induced calcium 217 
transients and contractions (twitch and tetanus) as well as physiological responses to increase 218 
in muscle length and stimulation frequency(24, 26) were reproducibly recorded in myobundles 219 
from ten donors. The specific blockade of acetylcholine-induced but not electrically-induced 220 
calcium release by the muscle relaxant and acetylcholine receptor blocker tubocurarine 221 
mimicked responses seen in human studies(32). Along with dose-dependent increase in 222 
calcium transient amplitude by caffeine, these experiments demonstrate that myofibers formed 223 
within the 3D myobundle culture environment exhibited intact excitation-contraction coupling 224 
and physiological responsiveness to both chemical and electrical stimuli. While repeated non-225 
invasive interrogation of myobundle function was limited to calcium imaging, integration of 226 
smaller size myobundles with high-throughput force testing assays should be feasible as 227 
demonstrated for mouse cells(15).  228 
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 The utility of myobundles as a preclinical drug testing platform was evaluated by 229 
measuring contractile and biochemical responses to statins, chloroquine, and clenbuterol. Statin 230 
myopathy is a common side effect that has been reported for all currently available statins(5, 231 
33). Similar to clinical reports, human myobundles showed higher sensitivity to cerivastatin than 232 
lovastatin(34) and at excessive statin concentrations displayed progressive weakness and lipid 233 
accumulation, suggestive of equivalent mechanisms of action in vitro and in vivo. The use of 234 
myobundles allowed direct comparison of similar pharmaceuticals on the same patient or 235 
cohort, previously recommended for but unavailable for statins due to the variations among 236 
clinical trials and underreporting of symptoms(5, 33). In response to an anti-malarial agent, 237 
chloroquine, myobundles showed induction of autophagic myopathy also observed in native 238 
muscle(36), thus providing a potential functional screen for non-toxic modulators of autophagy. 239 
We also tested the acute and chronic responses of myobundles to β2-adrenergic agonist 240 
clenbuterol and observed myofiber hypertrophy and increased contractile strength at low 241 
clenbuterol doses followed by muscle weakness at higher doses, consistent with previous 242 
animal and human studies(39). Currently, binding affinity   to  β2-adrenergic receptors is one of 243 
the standard tests for drug specificity(41) and is also a potential target for therapies in muscle 244 
wasting disorders(39). Overall, these results suggest that myobundles closely mimic the 245 
functional responses of native human muscle through multiple signaling pathways and could 246 
provide a pre-clinical assay for predictive screening of novel therapeutics for a broad range of 247 
muscle-related disorders.  248 
 Our in vitro model of human skeletal muscle provides a tool for improved predictive 249 
pharmacological testing and a potential alternative to costly animal studies. Non-destructive, 250 
real-time measurement of function such as calcium handling shown here could be combined 251 
with other optically-based assays(43) to elucidate mechanisms of drug action. The ability to 252 
measure and quantify functional endpoints in myobundles in a population- or patient-specific 253 
manner allows construction of pharmacological time- and dose-response curves previously not 254 
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available for human skeletal muscle. The myobundles may be integrated with other established 255 
human micro-organ systems such as liver or heart for more predictive body-on-chip toxicology 256 
studies(2). Functional acetylcholine receptors within myobundles are integral to studies 257 
involving the neuromuscular junctions and necessary for potential implantation of such tissues 258 
to repair muscle dysfunction or loss. Eventual applications of myobundle platform using patient-259 
derived cells to model functional deficits observed in different muscle pathologies may allow 260 
development of more efficacious therapies and safe translation to clinics. 261 
MATERIALS AND METHODS 262 
Preparation of Myogenic Cells 263 
Human skeletal muscle samples were obtained through standard needle biopsy or surgical 264 
waste under Duke University IRB approved protocols. Nine donor samples were expanded by 265 
outgrowth similar to methods previously described(6). Briefly, muscle samples were minced, 266 
washed in PBS, and enzymatically digested in 0.05% trypsin for 30 minutes. Muscle was 267 
collected by centrifugation, pre-plated for 2 hours, and transferred to a matrigel (BD) coated 268 
flask for attachment. Cells were expanded in skeletal muscle growth media containing low 269 
glucose DMEM, supplements purchased from Lonza (EGF, fetuin, dexamethasone, and 270 
gentamicin without insulin), and supplemented with 10% fetal calf serum as previously 271 
described(23). A second growth media containing 5 ng/mL bFGF and 20% fetal calf serum was 272 
used during optimization as it was previously shown to improve expansion of myogenic 273 
cells(22). Myogenic cells were either cryopreserved in 90% growth medium with 5% fetal calf 274 
serum and 5% DMSO at passage 1 or 2 then used at passage 3-5 for the generation of 275 
myobundles or staining. A sample of primary human skeletal myoblasts from additional donor 276 
was purchased from Lonza for comparison.  277 
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 For calcium imaging studies, expanded myogenic cells were transduced with a lentiviral 278 
vector encoding the fluorescent calcium reporter GCaMP6(28) driven by a myosin heavy chain-279 
creatine kinase promoter MHCK7(29) for muscle specific expression. 280 
 For the measurements of myofiber length and nuclei number, 5% of myogenic cells used 281 
for myobundle formation were transduced with a lentiviral vector encoding MHCK7 driven 282 
GFP(44). This allowed the visualization and measurement of individual GFP+ myotubes within 283 
myobundles using immunostaining and confocal microscopy. 284 
Fabrication of Human Myobundles  285 
Myobundles were formed by modifying our previously published methods for engineered rodent 286 
muscle tissues(13, 14) (Figure 1- figure supplement 2). Expanded myogenic cells were 287 
dissociated in 0.025% trypsin-EDTA to a single cell suspension and encapsulated in a 288 
fibrinogen (Akron) and matrigel (BD Biosciences) solution on laser cut Cerex® frames (9.2 x 9.5 289 
mm outer dimensions, 6.8 x 8.3 mm inner dimensions) within PDMS molds (cast from Teflon 290 
masters and pretreated with pluronic) at 15x106 cells/mL (7.5x105 cells per myobundle). 291 
Specifically, a cell solution (7.5x105 cells in 17.2 µL media per bundle + 2 µL of 50 unit/mL 292 
thrombin in 0.1% BSA in PBS (Sigma)) and a gelling solution (11 µL media + 10 µL Matrigel + 293 
10 µL of 20 mg/mL Fibrinogen in DMEM) were prepared in separate vials on ice for up to six 294 
myobundles per vial. Gelling solution was added to the cell solution and mixed thoroughly then 295 
each bundle was individual pipetted within the PDMS mold and onto the frame. The 296 
cell/hydrogel mixture was polymerized for 30 min at 37º C followed by incubation in growth 297 
media containing 1.5 mg/mL 6-aminocaproic acid (ACA, Sigma). Myobundles were kept in 298 
growth media during gel compaction (3-5 days) and then switched to low glucose DMEM 299 
(Gibco) with 2% horse serum (Hyclone), 2 mg/mL ACA and 10 µg/mL insulin (Sigma). Frames 300 
were removed from molds at the time of switch to low serum medium and cultured dynamically 301 
in suspension for an additional 1-4 weeks. Starting from a 50 mg donor biopsy, typical cell 302 
expansion for 5 passages can allow generation of at least 1000 myobundles with a total mass of 303 
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>5 g, representing a >100-fold amplification of muscle mass when going from native to 304 
engineered tissue system. 305 
 All drugs were purchased from Sigma. Clenbuterol hydrochloride, chloroquine 306 
phosphate, and cerivastatin sodium salt hydrate were prepared at 1000X stock solutions in PBS 307 
(control) and sterile-filtered for use. Lovastatin was prepared as a 10,000X stock solution in 308 
DMSO in which case DMSO was used as vehicle control. Drugs studies in myobundles or 2D 309 
cultures were initiated after one week of differentiation. Myobundles were replenished with fresh 310 
media and drug each day to maintain drug concentration. 311 
Measurement of Contractile Force  312 
Electrically or chemically stimulated contractile force generation in myobundles was measured 313 
using a custom force measurement set-up as previously described(13, 14). Briefly, single 314 
myobundles on a frame were transferred to the bath of the force measurement set-up, 315 
maintained at 37 ºC. One end of the bundle was secured by a pin to an immobile PDMS block 316 
and the other end was attached to a PDMS float connected to the force transducer mounted on 317 
a computer-controlled motorized linear actuator (Thor Labs). The sides of the frame were cut to 318 
allow myobundle stretch by the actuator and isometric measurement of contractile force. 319 
Initially, the myobundle was set to its baseline length using the motorized linear actuator. To 320 
assess the force-length relationship, myobundle was stretched by 2% of its culture length then 321 
stimulated by a 40V/cm, 10 ms electrical pulse using a pair of platinum electrodes and the twitch 322 
force was recorded. At 12% stretch, 1 second long stimulations at 5, 10, and 20 Hz were 323 
applied and the subsequent contractile force was recorded to assess the force-frequency 324 
relationship. Contractile force traces were analyzed for peak twitch or tetanus force, time to 325 
peak twitch, and half relaxation time using a custom MATLAB program. For studies with 326 
acetylcholine, 60 µL of drug solution was added to the 6 mL bath at t = 5 sec of recording.  327 
Imaging of Calcium Transients 328 
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Myobundles expressing the MHCK7-GcaMP6 reporter were non-destructively monitored for 329 
calcium transients following differentiation. A live imaging chamber with heated enclosure was 330 
used to maintain cells in physiological conditions during recording. Bundles were placed in 331 
sterile tyrode’s   solution   in   a   custom-designed glass-bottom bath containing electrodes for 332 
stimulation. Video-images were acquired using an Andor iXon camera affixed to a Nikon 333 
microscope with a FITC filter and either 4x or 10x objective. During studies with caffeine and 334 
acetylcholine, 60 µL of drug solution was added to the bath at t = 5 sec of recording. Video was 335 
analyzed using Andor Solis software and relative changes in fluorescence signal were 336 
calculated  by  ΔF/F = (Peak-Trough) / (Trough-Background) as previously described(14). 337 
Immunohistochemistry 338 
Cells were fixed in 4% paraformaldehyde in PBS for 10 minutes and myobundles were fixed in 339 
2% paraformaldehyde in PBS overnight at 4º C. Following fixation, samples were washed in 340 
PBS then blocked in 5% chick serum with 0.2% Triton-X 100. The following primary antibodies 341 
were used for tissue characterization: desmin (SCBT, 1:200), anti-GFP (Life Technologies, 342 
1:200), laminin (Abcam, 1:200), muscle creatine kinase (SCBT, 1:100), MyoD (BD, 1:100), 343 
myogenin (SCBT, 1:100), myosin heavy chain 1/2/4/6 (SCBT, 1:100), Pax7 (DSHB, 1:50), 344 
sarcomeric α-actinin (Sigma, 1:200), and vimentin (Sigma, 1:200). Corresponding fluorescently 345 
labeled secondary antibodies (1:200), α-bungarotoxin (1:100), and phalloidin (1:200) were 346 
purchased from Life Technologies. Oil Red O staining was performed using standard protocols 347 
on cryosections of myobundles fixed in 4% paraformaldehyde. Hematoxylin and eosin stain was 348 
performed on paraffin embedded sections of 2% paraformaldehyde fixed myobundles using 349 
Harris modified hematoxylin (Sigma) and Eosin Y (Sigma). Images were acquired using a Zeiss 350 
510 inverted confocal microscope and analyzed using LSM Image Software. Mosaic images for 351 
fiber length measurements were generated using Mosaic J in FIJI. 352 
Western Blotting  353 
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Cell or myobundle protein was isolated in RIPA lysis and extraction buffer with protease inhibitor 354 
(Sigma). Protein concentration was determined using BCA assay (Pierce) according to 355 
manufacturer’s   instructions.  Western   blot   was   performed   using   Bio- RadMini-PROTEAN gels 356 
and the Mini-PROTEAN Tetra cell, Mini Trans-blot module. The following primary antibodies 357 
were used for detection: GAPDH (SCBT, 1:500), LC3 (Cell Signaling, 1:200), muscle creatine 358 
kinase (SCBT, 1:200), myosin heavy chain 1/2/4/6 (SCBT, 1:200), and sarcomeric alpha-actinin 359 
(Sigma, 1:200). HRP conjugated anti-mouse (1:20,000) and anti-goat (1:5000) antibody were 360 
purchased from Sigma, and HRP conjugated anti-rabbit was purchased from SCBT (1:5000). 361 
Chemiluminescence was performed using Clarity Western ECL substrate (Bio-Rad). Images 362 
were acquired using a Bio-Rad Chemidoc and analyzed using ImageJ. 363 
Statistics  364 
Results are presents as mean ± SD. Statistical significance was determined by unpaired t-test 365 
or one-way ANOVA with post-hoc Bonferroni-Holm test. P<0.05 was considered statistically 366 
significant.  367 
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 473 
FIGURE LEGENDS 474 
Figure 1. Structure and cellular composition of myobundles.  475 
(A) Human myogenic precursors were cast within a fibrin/matrigel matrix in PDMS molds and 476 
anchored to nylon frames. Once compacted, frames with myobundles were removed for free-477 
floating culture. (B) F-actin+ myofibers shown within 2-week myobundles are aligned and 478 
surrounded by laminin. (C) Transverse myobundle cross-section showing dense, uniformly 479 
distributed myosin heavy chain (MYH) expressing myofibers. (D-F) Aligned myofibers within 480 
myobundle  show  striated  pattern  of  the  contractile  protein  sarcomeric  α-actinin (SAA) (D), 481 
myogenin (MyoG) positive nuclei (E), and bungarotoxin-labeled acetylcholine receptors (AChR) 482 
(F). (G) Pax7+ cells (arrows) are found abutting myofibers suggesting regenerative potential. (H) 483 
Myofiber diameter increases with time in culture, with significant enhancement at 3 and 4 weeks 484 
versus 1 week (*, p<0.05, N=4 donors, n> 10 myofibers per myobundle). (I) Structural 485 
maturation is also evident from increased expression of muscle markers MYH, SAA, and muscle 486 
creatine kinase (MCK). Scale bars: (B-F) scale = 50 µm, (G) scale = 25 µm. 487 
Figure 2. Contractile function of myobundles.  488 
(A) Representative contractile force traces of a 3-week myobundle showing fusion of individual 489 
twitches into a stronger tetanic contraction induced by increased stimulation frequency. (B) 490 
Representative increase in both contractile (active) force and passive tension with increase in 491 
myobundle length for one donor at 3 weeks in culture (n=3 myobundles). (C) Twitch and tetanus 492 
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forces increase over time in culture with significant enhancement at 4 weeks versus 1 week (*, 493 
p<0.05, n=4 myobundles). (D) Kinetics of twitch rise and relaxation do not vary over 4 weeks in 494 
culture (n=4 myobundles). (E) Specific twitch and tetanus force and tetanus-to-twitch ratio for 495 
different cell sources (D1-D9, donors 1-9; CS, commercial source, Lonza). (F) Kinetics of twitch 496 
response for different cell sources.  497 
Figure 3. Calcium handling of myobundles.     498 
(A) Myofiber-specific expression of GCaMP6 in lentivirally transduced myobundles. SAA, 499 
sarcomeric  α-actinin (scale bar = 50 µm). (B) Time course of GCaMP6 fluorescence during a 500 
single electrically stimulated twitch (scale bar = 200 µm) . (C) Representative fluorescence 501 
traces from 1 Hz and 10 Hz stimulations of 2-week old myobundles. (D) Amplitude of electrically 502 
stimulated calcium transient increases with time of culture and myobundle maturation (*, p<0.05 503 
vs. 1 week, n=4 myobundles). (E) Representative fluorescence trace of acetylcholine (ACh, 100 504 
mM bolus) stimulated calcium release in a 2-week myobundle. (F) ACh receptor blocker 505 
tubocurarine (25 µM) specifically and significantly reduces ACh induced calcium release without 506 
affecting electrically stimulated calcium transients (*, p<0.05, n=5 myobundles). Note that 507 
amplitude of Ach-induced calcium release is similar to that of calcium transient induced by 508 
tetanic (10 Hz) electrical stimulation. 509 
 510 
Figure 4. Pharmacological validation of myobundles. 511 
 (A-B) Two-week application of cerivastatin (A) and lovastatin (B) at increasing doses 512 
significantly reduced tetanus force, normalized to untreated or vehicle treated (DMSO for 513 
Lovastatin) control (n=4 myobundles per donor). (C) Accumulation of lipids in myobundles, 514 
evaluated by Oil Red O stain, was absent from controls, moderate at lower concentrations, and 515 
considerable at higher concentrations of both statins (scale bar = 50 µm). (D-F) One-week 516 
exposure of myobundles to chloroquine resulted in dose-dependent decrease of contractile 517 
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force (n=4 myobundles per donor) (D) as well as increased expression of the autophagic 518 
pathway marker LC3B-II  and  decreased  expression  of  contractile  protein  sarcomeric  α-actinin 519 
(SAA) (E-F, n=4 myobundles per donor). (A-F) (*, p<0.05 vs. 0 µM, #, p<0.05 vs. all other 520 
concentrations). (G) Acute (thirty-minute) and (H) chronic (two-week) application of clenbuterol 521 
to myobundles (shown in different donors) results in a dose-dependent increase in contractile 522 
force with peak effects observed at 1 µM (acute) and 0.1 µM (chronic) and significant reduction 523 
in force generation observed at 100 µM (acute, n=3 myobundles; chronic, n=4 myobundles). (I) 524 
Chronic administration of 0.1 µM Clenbuterol induced hypertrophy of myofibers as evident from 525 
a rightward shift in their diameter distribution and significant increase in the average myofiber 526 
diameter  (untreated,  15.7±0.3  µm  vs  0.1  µM  clenbuterol,  17.1±0.6  µm,  *,  p<0.05,  n  ≥  55  527 
myofibers per myobundle, pooled for 3 myobundles).  528 
 529 
VIDEO LEGENDS 530 
Video 1. Spontaneous contractions of human myobundles.  531 
Following three to five days of differentiation within the hydrogel construct, myofibers began 532 
spontaneously contracting. These contractions typically last for a few days, and are rarely seen 533 
beyond two weeks following differentiation. Video is shown in real time for 26 sec duration and 534 
at field of view of 2x1.5 mm then 0.8x0.6 mm. 535 
Video 2. Stimulated contractions of human myobundles. Myobundles respond to electrical 536 
stimulation by forceful contraction. Here, a myobundle pair is contracting in concert with 1 Hz 537 
electrical stimulation with enough force to bend the frame on which it is attached. Video is  538 
shown in real time for 17 sec duration and at field of view of 25x25 mm. 539 
Video 3. GCaMP6 reported calcium release of human myobundles. Myobundles formed using 540 
myogenic precursors that were lentivirally transduced with a GCaMP6 calcium reporter contain 541 
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myofibers that produce fluorescence signal in response to calcium release. Here, myobundles 542 
show calcium release in response to both twitch (1 Hz) and tetanus (10 Hz) electrical 543 
stimulation. Video is shown in real time for 36 sec duration and at field of view of 500x500 µm. 544 
Video 4. Caffeine induced calcium release in human myobundles. Similar to human skeletal 545 
muscle, application of caffeine to myobundles induces calcium release via the ryanodine 546 
receptors. This lease to an increase in fluorescence from the GCaMP calcium reporter. Video is  547 
shown in real time for 66 sec duration and at field of view of 2x2 mm. 548 
Video 5. Acetylcholine induced calcium release from human myobundles. Function of 549 
myobundle acetylcholine receptors was confirmed by GCaMP6 detected calcium release in 550 
response to a bolus of 10 mM acetylcholine. Myobundle response to acetylcoline was 551 
significantly blocked by the muscle relaxant tubocurarine similar to that observed clinically in 552 
human skeletal muscle. Video is shown in real time for 75 sec duration and at field of view of 553 
2x2 mm. 554 
 555 
SUPPLEMENTARY FIGURE LEGENDS 556 
Figure 1 – figure supplement 1. Myogenicity of donor cells during expansion.  557 
(A) Expanded donor cells at passage three still express the muscle precursor markers desmin 558 
and (B) MyoD. (C) After switch to low serum media in 2D, myogenic cells fuse into myotubes 559 
and express myogenin (MyoG) and sarcomeric alpha-actinin (SAA). Scale bars: (A) 50 µm, (B-560 
C) 200 µm. 561 
 562 
Figure 1 – figure supplement 2. Schematic of myobundle fabrication. (A) Machined teflon 563 
masters were used to generate multiple replicas of PDMS molds. The PDMS molds contain an 564 
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outer ridge that fit laser-cut frames made of porous Cerex® material. (B) Separate solutions 565 
containing myogenic cells and hydrogel proteins were prepared on ice and mixed immediately 566 
prior to pipetting into the PDMS mold with frame. (C) Images depicting the appearance of the 567 
myobundles during the course of culture. At far left, the cell/hydrogel solution is gelled at 37oC in 568 
a tissue culture incubator for 30 min. Following gelation, culture media is added to the well. 569 
Within 4 days, the myobundles compact and the edges come away from the PDMS mold. The 570 
compacted myobundles are removed from the mold and cultured free-floating. Scale bar = 5 571 
mm. 572 
 573 
Figure 1 – figure supplement 3. Characterization of myobundle architecture.  574 
(A) Representative composite image of a myobundle consisting of aligned, F-actin+ myofibers 575 
surrounded by a layer of vimentin+ fibroblasts on the outer surface. (B, C) Hematoxylin and 576 
eosin stain at lower (B) and higher (C) magnification show uniform density of aligned, 577 
multinucleated myofibers at 3 weeks of culture. (D) F-actin+ immunostaining shows increased 578 
myofiber diameter with time in culture. Scale bars: (A) 500 µm, (B) 200 µm  (C,D) = 50 µm. 579 
 580 
Figure 1 – figure supplement 4. Characterization of myofiber length and myonuclei 581 
number.  582 
(A) Representative composite image of a 3-week differentiated myobundle formed using 5% 583 
GFP expressing myogenic cells to visualize individual myofibers. Scale bar = 500 µm. (B) The 584 
average length of GFP+ myofibers as a function of differentiation time (20-50 myofibers per 585 
bundle, n=4-6 myobundles per time point). (C) Histogram of myonuclei number per GFP+ 586 
myofiber in 3-week myobundles with average and median myonuclei numbers of 7±3.6 and 6, 587 
respectively (n=127 myofibers from 6 myobundles).  588 
 589 
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Figure 2 – figure supplement 1. Optimization of myogenic cell expansion using two 590 
different media.  591 
(A) Myogenic cells expanded in the two different media containing either bFGF or EGF had 592 
similar fractions of MyoD+ cells. (B) Upon differentiation in 2D culture, these cells expressed 593 
similar levels of myogenin (n=3 coverslips) (C) Cells expanded in EGF containing media formed 594 
myobundles with significantly higher levels of contractile force than those expanded in bFGF 595 
containing media. (N=2 donors, n=4 myobundles, *, p<0.05) 596 
 597 
Figure 2 – figure supplement 2. Force-frequency relationship of myobundles.  598 
Contractile force increases with stimulation frequency. (n=4 myobundles; *, p<0.05 vs. 1 Hz; #, 599 
p<0.05 vs. 1 Hz and 5 Hz) 600 
 601 
Figure 3 – figure supplement 1. Correlation of contractile force and calcium transients. 602 
Each point represents a single bundle calcium transient plotted against the corresponding force, 603 
either twitch or tetanus (at 10 Hz). Data was obtained from myobundles during 4 weeks in 604 
culture prepared from the same pool of MHCK7-GCaMP6 transduced myogenic precursors. 605 
 606 
Figure 3 – figure supplement 2. Caffeine induced calcium transients.  607 
(A) A bolus of caffeine of different concentrations was added to the bath during video imaging 608 
and resulted in an increase in relative fluorescence amplitude (ΔF/F). (B) ΔF/F at 30 seconds 609 
following caffeine administration was calculated and positively correlated with caffeine 610 
concentration.  (Donor A, n=3 myobundles; Donor B n=4 myobundles; *, p < 0.05 vs. 20 mM) 611 
 612 
Figure 3 – figure supplement 3. Myobundle response to acetylcholine.  613 
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(A) Myobundles exhibited a similar amplitude of calcium release in response to acetylcholine 614 
(Ach) throughout four weeks in culture. (n=4) (B) Representative trace of contractile force for a 615 
3-week myobundle in response to a bolus of acetylcholine. (C) The amplitude of acetylcholine 616 
induced contractile force was similar to that induced by tetanic electrical stimulation. Incubation 617 
of myobundles with the ACh receptor blocker tubocurarine reduced acetylcholine induced 618 
contractile force without affecting electrically stimulated contraction at 3 weeks in culture. (n=5, 619 
*, p<0.05) (D) Amplitudes of calcium and contractile force responses to ACh are similar to those 620 
during tetanic electrical stimulation in myobundles from different donors. (A, n=5 myobundles; B, 621 
n=3 myobundles) 622 
Figure 4 – figure supplement 1. Biochemical responses of human 2D myotube and 3D 623 
myobundle cultures to chloroquine. Human myogenic cells from a single donor were 624 
differentiated on 2D Matrigel coated dishes (black) or in 3D myobundles (white) then treated for 625 
one week with varying doses of chloroquine. The biochemical response of 2D and 3D muscle 626 
models were evaluated by western blot (A) and shown to be similar for (B) the dose-depended 627 
accumulation of LC3B-II and the reduction of contractile proteins (C) sarcomeric alpha actinin 628 
(SAA) and (D) myosin heavy chain  (MYH) (n=4 2D wells or myobundles, #, p<0.05 vs. control 629 
and 1 µM).  630 
Figure 4 – figure supplement 2. Improved myobundle function following clenbuterol 631 
treatment.  632 
(A) Clenbuterol-induced increase in force was reproduced among multiple donors following two 633 
week treatment (n=4 myobundles per donor, *, p<0.05). Dose response for donor A is shown in 634 
Figure 4H. (B) Clenbuterol increased myofiber diameter, visualized by F-actin staining. Scale 635 
bar = 100 µm. Quantification of these immunostainings is shown in Figure 4l. 636 
 637 
Source Code file contains custom MATLAB code used in this study. 638 




